Kunal Kishnani

Kunal Kishnani

President, Kriya Rare Disease

  • Bio
    Kunal Kishnani is the President of Kriya Rare Disease. He most recently served as Founder and Chief Executive Officer of Warden Bio until its acquisition by Kriya in late 2021. Prior to founding Warden Bio, Mr. Kishnani was Principal, Corporate Development at Roivant Sciences, where he was responsible for helping to evaluate and negotiate new investment opportunities, including Roivant’s $3 billion strategic alliance with Sumitomo Dainippon Pharma. Mr. Kishnani also previously served as Co-Founder and Head of Operations at Genevant, where he was instrumental in a variety of milestones, including its company-launching spinout, initial financing, business operations achievements, and multiple collaborations with major pharmaceutical companies. Earlier in his career, Mr. Kishnani served as Director of Special Projects at Roivant Sciences and as R&D Chief of Staff at Axovant Sciences. Mr. Kishnani received degrees in finance and accounting from Elon University.